3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
5
Thoracic
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
60
Breast Neoplasms, Male
9
Carcinoma, Intraductal, Noninfiltrating
5
Breast Carcinoma In Situ
5
Triple Negative Breast Neoplasms
4
Inflammatory Breast Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Uterine Cervical Neoplasms
2
Salivary Gland Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Vulvar Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Penile Neoplasms
1
Interventions
spartalizumab
2
durvalumab
2
zanidatamab
1
tremelimumab
1
trastuzumab deruxtecan
1
tislelizumab
1
pembrolizumab
1
obinutuzumab
1
naptumomab estafenatox
1
Trastuzumab
1
Polymerase Chain Reaction
1
Nivolumab
1
Mass Spectrometry
1
In Situ Hybridization, Fluorescence
1
Immunohistochemistry
1
Gemcitabine
1
Capecitabine
1
Albumin-Bound Paclitaxel
1
Ado-Trastuzumab Emtansine
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma Of Esophagus
×
Immunohistochemistry
×
Breast
×
Clear all
NCT00900094
2012-02-07
IRB 2000-294
University of Michigan Rogel Cancer Center
Completed
200 enrolled